PAVmed Chairman and Chief Executive Officer Lishan Aklog, M.D., Elected to AdvaMed Board of Directors
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the Advanced Medical Technology Association (AdvaMed), the world’s leading medical technology trade association, has appointed Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer to its Board of Directors.
“Lishan is an established leader in our industry and we welcome his addition to our Board,” said Scott Whitaker, President and CEO of AdvaMed. “His long career as both a cardiac surgeon and as a medical device entrepreneur is a natural fit for AdvaMed. His innovative work with PAVmed, addressing unmet needs in clinical care, aligns with our mission to improve the lives of patients around the world. We look forward to his perspective and expertise as we work together to solve the issues facing our members and the medtech industry.”
Headquartered in Washington, DC, AdvaMed is the world’s largest and most influential trade association focused on advancing medical technology to achieve healthier lives and healthier economies around the world. The organization promotes competitive policies that foster the highest ethical standards, rapid product approvals, appropriate reimbursement, and access to international markets for the medical device and diagnostics industry. Its AdvaMed Accel and AdvaMedDx divisions are dedicated to addressing the specific needs and challenges of smaller medical technology companies and medical diagnostic companies, respectively. Dr. Aklog was also elected to AdvaMed Accel’s separate Board of Directors.
“I am honored to have been elected to the AdvaMed Board of Directors during this transformational period for our industry and the broader health care system,” said Dr. Aklog. “For more than two decades, since my early days as a young heart surgeon working closely with industry on medical device innovation, I have witnessed the critical role AdvaMed plays as the ‘center of gravity’ of our industry. Today, as the leader of a dynamic, up-and-coming medtech company, I see what powerful and effective allies AdvaMed, AdvaMedDx and AdvaMed Accel are to their member companies navigating complex regulatory and reimbursement dynamics to commercialize our products.”
“I am excited to join my esteemed colleagues on the Board, including many prominent leaders of our industry whom I have long admired and respected, to help AdvaMed advocate for the highest ethical standards and broad access to safe, effective and innovative medical technologies that save and improve lives,” concluded Aklog.
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. AdvaMed acts as the common voice for companies producing medical devices, diagnostic products and digital health technologies. For more information, visit www.advamed.org.
PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company employing a unique business model designed to advance innovative products to commercialization rapidly and with less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation while seeking to further expand its pipeline through relationships with its network of clinician innovators at leading academic centers. PAVmed’s diversified product pipeline addresses unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its four operating divisions include GI Health (EsoGuard® Esophageal DNA Test, EsoCheck® Esophageal Cell Collection Device, and EsoCure™ Esophageal Ablation Device with Caldus™ Technology), Minimally Invasive Interventions (CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome), Infusion Therapy (PortIO™ Implantable Intraosseus Vascular Access Device and NextFlo™ Highly Accurate Disposable Intravenous Infusion Set), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit www.EsoGuard.com and follow us on Twitter, Facebook and Instagram.
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s preclinical studies; whether and when PAVmed’s products are cleared by regulatory authorities; market acceptance of PAVmed’s products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company’s financial and operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed’s control. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s future operations, see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
Director of Investor Relations
Chief Commercial Officer
Released March 1, 2021